164 related articles for article (PubMed ID: 32583529)
1. Effect of reoxygenation on hypofractionated radiotherapy of prostate cancer.
Kuperman VY; Lubich LM
Med Phys; 2020 Oct; 47(10):5383-5391. PubMed ID: 32583529
[TBL] [Abstract][Full Text] [Related]
2. The minimal FLASH sparing effect needed to compensate the increase of radiobiological damage due to hypofractionation for late-reacting tissues.
Böhlen TT; Germond JF; Bourhis J; Bailat C; Bochud F; Moeckli R
Med Phys; 2022 Dec; 49(12):7672-7682. PubMed ID: 35933554
[TBL] [Abstract][Full Text] [Related]
3. A radiobiological model of reoxygenation and fractionation effects.
Guerrero M; Carlson DJ
Med Phys; 2017 May; 44(5):2002-2010. PubMed ID: 28273349
[TBL] [Abstract][Full Text] [Related]
4. Variability of α/β ratios for prostate cancer with the fractionation schedule: caution against using the linear-quadratic model for hypofractionated radiotherapy.
Cui M; Gao XS; Li X; Ma M; Qi X; Shibamoto Y
Radiat Oncol; 2022 Mar; 17(1):54. PubMed ID: 35303922
[TBL] [Abstract][Full Text] [Related]
5. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial.
Widmark A; Gunnlaugsson A; Beckman L; Thellenberg-Karlsson C; Hoyer M; Lagerlund M; Kindblom J; Ginman C; Johansson B; Björnlinger K; Seke M; Agrup M; Fransson P; Tavelin B; Norman D; Zackrisson B; Anderson H; Kjellén E; Franzén L; Nilsson P
Lancet; 2019 Aug; 394(10196):385-395. PubMed ID: 31227373
[TBL] [Abstract][Full Text] [Related]
6. Radiobiology of hypofractionated stereotactic radiotherapy: what are the optimal fractionation schedules?
Shibamoto Y; Miyakawa A; Otsuka S; Iwata H
J Radiat Res; 2016 Aug; 57 Suppl 1(Suppl 1):i76-i82. PubMed ID: 27006380
[TBL] [Abstract][Full Text] [Related]
7. The radiobiology of prostate cancer including new aspects of fractionated radiotherapy.
Fowler JF
Acta Oncol; 2005; 44(3):265-76. PubMed ID: 16076699
[TBL] [Abstract][Full Text] [Related]
8. What hypofractionated protocols should be tested for prostate cancer?
Fowler JF; Ritter MA; Chappell RJ; Brenner DJ
Int J Radiat Oncol Biol Phys; 2003 Jul; 56(4):1093-104. PubMed ID: 12829147
[TBL] [Abstract][Full Text] [Related]
9. [Hypofractionated irradiation of prostate cancer: What is the radiobiological understanding in 2017?].
Cosset JM
Cancer Radiother; 2017 Oct; 21(6-7):447-453. PubMed ID: 28847464
[TBL] [Abstract][Full Text] [Related]
10. Optimal fractionation in radiotherapy for non-small cell lung cancer--a modelling approach.
Lindblom E; Dasu A; Toma-Dasu I
Acta Oncol; 2015; 54(9):1592-8. PubMed ID: 26217986
[TBL] [Abstract][Full Text] [Related]
11. Theoretical effectiveness of cell survival in fractionated radiotherapy with hypoxia-targeted dose escalation.
Chvetsov AV; Rajendran JG; Zeng J; Patel SA; Bowen SR; Kim EY
Med Phys; 2017 May; 44(5):1975-1982. PubMed ID: 28236652
[TBL] [Abstract][Full Text] [Related]
12. In Vitro Radiobiological Advantages of Hypofractionation Compared with Conventional Fractionation: Early-Passage NSCLC Cells are Less Aggressive after Hypofractionation.
Zhang H; Wan C; Huang J; Yang C; Qin Y; Lu Y; Ma J; Wu B; Xu S; Wu G; Yang K
Radiat Res; 2018 Dec; 190(6):584-595. PubMed ID: 30234458
[TBL] [Abstract][Full Text] [Related]
13. Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: α/β = 1.4 (0.9-2.2) Gy.
Miralbell R; Roberts SA; Zubizarreta E; Hendry JH
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):e17-24. PubMed ID: 21324610
[TBL] [Abstract][Full Text] [Related]
14. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
15. Effect of intratumor heterogeneity on BED for hypofractionated dose regimens.
Kuperman VY
Med Phys; 2019 Oct; 46(10):4690-4698. PubMed ID: 31257607
[TBL] [Abstract][Full Text] [Related]
16. Hypofractionation for clinically localized prostate cancer.
Hickey BE; James ML; Daly T; Soh FY; Jeffery M
Cochrane Database Syst Rev; 2019 Sep; 9(9):CD011462. PubMed ID: 31476800
[TBL] [Abstract][Full Text] [Related]
17. Is biochemical relapse-free survival after profoundly hypofractionated radiotherapy consistent with current radiobiological models?
Tree AC; Khoo VS; van As NJ; Partridge M
Clin Oncol (R Coll Radiol); 2014 Apr; 26(4):216-29. PubMed ID: 24529742
[TBL] [Abstract][Full Text] [Related]
18. Comparative radiobiological analysis and preliminary results of Ultra hypofractionated accelerated radiotherapy for low-risk prostate cancer patients.
Nanos C; Souftas V; Zisimopoulos A; Abatzoglou I; Koukourakis MI
J BUON; 2021; 26(3):956-963. PubMed ID: 34268959
[TBL] [Abstract][Full Text] [Related]
19. Hypofractionation: what does it mean for prostate cancer treatment?
Liao Y; Joiner M; Huang Y; Burmeister J
Int J Radiat Oncol Biol Phys; 2010 Jan; 76(1):260-8. PubMed ID: 19879698
[TBL] [Abstract][Full Text] [Related]
20. Impact of prolonged fraction delivery times on tumor control: a note of caution for intensity-modulated radiation therapy (IMRT).
Wang JZ; Li XA; D'Souza WD; Stewart RD
Int J Radiat Oncol Biol Phys; 2003 Oct; 57(2):543-52. PubMed ID: 12957268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
